Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...2728293031323334353637...3940»
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    [VIRTUAL] Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1) (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_570;    
    P3
    Clinically beneficial weight loss of ≥10% was achieved by over two-thirds of participants and ≥20% by one-third of participants, along with associated improvements in cardiometabolic risk factors and physical functioning. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
    Clinical, Journal:  Semaglutide injection for the treatment of adults with type 2 diabetes. (Pubmed Central) -  Jan 29, 2021   
    As well as the SUSTAIN trial programme we used PubMed to identify relevant publications. This section discusses the position of semaglutide and the risks and benefits versus other once weekly GLP-1RAs and finally the development of an oral version of semaglutide, which has recently been approved in the United States.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
    Clinical, Journal:  Safety of injectable semaglutide for type 2 diabetes. (Pubmed Central) -  Jan 28, 2021   
    An increase in diabetic retinopathy (DR) events in the SUSTAIN 6 trial is the most concerning safety signal. Caution regarding DR is needed when initiating semaglutide and recommendations are suggested.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial initiation date:  NOVO-GLP1: Treatment of GLP-1 for Diabetic Bariatric Patients (clinicaltrials.gov) -  Jan 19, 2021   
    P4,  N=126, Not yet recruiting, 
    UMIN000042369 in the University Hospital Medical Information Network (UMIN); jRCT1011200008 in the Japan Registry of Clinical Trials (jRCT); pre-results. Initiation date: Dec 2020 --> Apr 2021
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
    [VIRTUAL] Difference in estimated glomerular filtration rate (eGFR) amongst different races: two case reports () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_2583;    
    Her A1C was 7.4 percent on a regimen consisting of aspirin 81 mg DR once daily, atorvastatin (Lipitor) 40 mg once daily, dapagliflozin (Farxiga) 10 mg once daily, glipizide (Glucotrol) 10 mg twice daily before meals, lisinopril (Prinivil, Zestril) 20 mg once daily, atenolol (Tenormin) 50 mg once daily, and metformin (Glucophage) 1,000 mg twice daily with meals...During the visit, the patient’s dapagliflozin had to be discontinued as her eGFR trended downwards below 45 mL/min overtime and unfortunately the patient’s insurance would not cover for canagliflozin...In June, her A1C was 6.5 percent on a regimen consisting of 6 units injected daily of insulin lispro protamin-lispro (Humalog Mix 75-25 Kwikpen, U-100), metformin (Glucophage-XR) 500 mg 24 hr tablet twice daily with meals, semaglutide (Ozempic) 0.5 mg (2 mg/1.5 mL) weekly, valsartan (Diovan) 160 mg once daily, and atorvastatin (Lipitor) 40 mg once daily...Although more studies are needed to further elucidate this potential risk, it is important for practitioners to recognize the risks associated with underestimation and overestimation of GFR. The overestimation of GFR in African Americans/Black patients, especially high-risk patients, can lead to major clinical consequences.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
    [VIRTUAL] Clinical impact of changing glucagon-like peptide 1 (GLP-1) receptor agonists to semaglutide () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_2533;    
    The results suggest that changing from an alternative GLP-1 receptor agonist to subcutaneous semaglutide is an effective strategy to optimize glycemic control and may help further reduce cardiovascular risk by decreasing weight and BMI while minimizing adverse effects such as tachycardia or retinopathy. Changes to background T2DM medications may have influenced the results as increased usage of insulin and SGLT-2 inhibitors can reduce HbA1c levels, as well as contribute to body weight changes; however, average doses of insulin did decrease after switching to subcutanous semaglutide.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    [VIRTUAL] Clinical impact of transitioning from once-daily injectable liraglutide to once-weekly injectable semaglutide in a Veteran population () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_733;    
    Purpose: Per the 2020 ADA Standards of Medical Care in Diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 agonists) should be selected as first-line dual therapy in combination with metformin for patients with type 2 diabetes with comorbid ASCVD to reduce major cardiovascular events and/or mortality...The primary outcome assessed was change in A1c between the last A1c measured when the patient was on liraglutide and the A1c at 3, 6, and/or 12 months as available following the transition to semaglutide. Secondary outcomes included achievement of individualized A1c goal, change in patient weight and BMI following transition, semaglutide adherence and tolerability, change in concurrent antidiabetic medications, method of dose transition from liraglutide to semaglutide, reason for transition, and cost-effectiveness of the transition.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal:  Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide? (Pubmed Central) -  Dec 23, 2020   
    Most importantly, subcutaneous semaglutide has already been shown to be superior to placebo in reducing cardiovascular risk, whereas the study of this with oral semaglutide will not be completed until 2024. Secondly, it is debatable whether subjects will find the daily protocol for taking oral semaglutide more convenient than that for the weekly subcutaneous formulation.
  • ||||||||||  semaglutide SC once-daily (NN9536) / Novo Nordisk
    Clinical, Review, Journal:  Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. (Pubmed Central) -  Nov 21, 2020   
    Randomized controlled trials (RCTs) have consistently shown glycemic and extra-glycemic benefits of long-acting injectable glucagon-like-peptide-1 receptor agonists (GLP-1RAs, liraglutide, albiglutide, exenatide once-weekly, dulaglutide, and semaglutide) in terms of reduction in the rates of cardiovascular events and mortality among patients with type 2 diabetes...Finally, multiple RWS reported better cardio-renal outcomes with GLP-1RAs than with DPP-4i, while initial findings from RWS described a weaker cardiovascular protection compared to SGLT-2i. Therefore, there is the need for further RWS and RCTs comparing these different classes of glucose lowering medications.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Journal, HEOR:  Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. (Pubmed Central) -  Nov 19, 2020   
    Once-weekly semaglutide 0.5 mg and 1 mg were associated with incremental cost-effectiveness ratios of EUR 2,285 and EUR 161 per QALY gained, respectively, versus empagliflozin 10 mg, and EUR 3,090 and EUR 625 per QALY gained, respectively, versus empagliflozin 25 mg. Based on a willingness-to-pay threshold of EUR 30,000 per QALY gained, once-weekly semaglutide 0.5 mg and 1 mg were projected to be cost-effective versus empagliflozin 10 mg and 25 mg for treatment of patients with T2D with inadequate glycemic control on oral anti-hyperglycemic medications in the Spanish setting, irrespective of patients' BMI at baseline.